155 related articles for article (PubMed ID: 18680235)
21. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Solomon SD; Wittes J; Finn PV; Fowler R; Viner J; Bertagnolli MM; Arber N; Levin B; Meinert CL; Martin B; Pater JL; Goss PE; Lance P; Obara S; Chew EY; Kim J; Arndt G; Hawk E;
Circulation; 2008 Apr; 117(16):2104-13. PubMed ID: 18378608
[TBL] [Abstract][Full Text] [Related]
22. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
Farley JH; Truong V; Goo E; Uyehara C; Belnap C; Larsen WI
Gynecol Oncol; 2006 Nov; 103(2):425-30. PubMed ID: 16677697
[TBL] [Abstract][Full Text] [Related]
23. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
Ashcroft DM; Chapman SR; Clark WK; Millson DS
Ann Pharmacother; 2001; 35(7-8):829-34. PubMed ID: 11485128
[TBL] [Abstract][Full Text] [Related]
24. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
Caldwell B; Aldington S; Weatherall M; Shirtcliffe P; Beasley R
J R Soc Med; 2006 Mar; 99(3):132-40. PubMed ID: 16508052
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of additional 200-mg dose of celecoxib in adult patients with postoperative pain following extraction of impacted third mandibular molar: a multicenter, randomized, double-blind, placebo-controlled, phase II study in Japan.
Saito K; Kaneko A; Machii K; Ohta H; Ohkura M; Suzuki M
Clin Ther; 2012 Feb; 34(2):314-28. PubMed ID: 22284900
[TBL] [Abstract][Full Text] [Related]
26. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Song YW; Lee EY; Koh EM; Cha HS; Yoo B; Lee CK; Baek HJ; Kim HA; Suh Y; Kang SW; Lee YJ; Jung HG
Clin Ther; 2007 May; 29(5):862-873. PubMed ID: 17697905
[TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
28. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study.
Cheung R; Krishnaswami S; Kowalski K
Clin Ther; 2007; 29 Suppl():2498-510. PubMed ID: 18164917
[TBL] [Abstract][Full Text] [Related]
29. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
33. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
34. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.
Schumacher HR; Berger MF; Li-Yu J; Perez-Ruiz F; Burgos-Vargas R; Li C
J Rheumatol; 2012 Sep; 39(9):1859-66. PubMed ID: 22859357
[TBL] [Abstract][Full Text] [Related]
36. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
37. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
39. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
[TBL] [Abstract][Full Text] [Related]
40. Clinical Questions #6. Does celecoxib increase cardiovascular risk?
Mayer BJ; Lamfers R; Feldstein DA
WMJ; 2005 Nov; 104(8):15-6. PubMed ID: 16425910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
